Placeholder Banner

BIO Files Amicus Brief Supporting Supreme Court Review of “Double Patenting” Doctrine and its Role in Patent Term Adjustments

June 21, 2024

BIO filed an amicus brief supporting Supreme Court review of a recurring question about the common-law “double patenting” doctrine and its interplay with the statutory adjustment of the patent term due to patent examination delays in the USPTO. The brief argues that current jurisprudence creates traps for patent applicants and penalizes owners of related patents that have different expiration dates solely due to USPTO inefficiencies. The Patent Act’s explicit provisions governing the calculation of patent term should have precedence over the judge-made nonstatutory double patenting doctrine.

Previously, BIO filed two amicus briefs in the U.S. court of Appeals for the Federal Circuit regarding this case. To review these two briefs, please refer to the Related Resources section.

In re Cellect - Fed. Cir. Pet. for Rehearing

In re Cellect - Fed. Cir.

Related Resources
BIO Files Amicus Brief Supporting Supreme Court Review of “Double Patenting” Doctrine and its Role in Patent Term Adjustments
Discover More
BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases.The Court of Appeal decision operates from a misunderstanding of the drug development and FDA…
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…
BIO filed an amicus brief in the U.S. Court of Appeals for the Sixth Circuit, seeking the reversal of a lower court's ruling that would set aside the 2022 rescission of the Securities and Exchange Commission (SEC) 2020 Rule regulating proxy advisory…